Evidence syntheses — page 6
140 structured review questions, each with a registered PICO frame, a reproduced search, an included-studies table, a summary of findings and an amendment log.
Reviews
-
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of CJC-1295 compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Low12 Dec 2024 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation with CJC-1295 compared with its comparator?
Low17 Apr 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Dulaglutide compared with the comparator used in its contributing trials on the anchor outcome for this…
High21 Feb 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Dulaglutide compared with its comparator?
High27 Nov 2024 -
In the population defined for cutaneous wound healing and tissue repair, what is the effect of GHK-Cu compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Low19 Sep 2025 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with GHK-Cu compared with its comparator?
Low02 Dec 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Gonadorelin compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate29 Aug 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation with Gonadorelin compared with its comparator?
Moderate23 Jan 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Kisspeptin-10 compared with the comparator used in its contributing trials on the anchor outcome for this…
Moderate11 Oct 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation with Kisspeptin-10 compared with its comparator?
Moderate26 Jun 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Larazotide acetate compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate01 Mar 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with Larazotide acetate compared with its comparator?
Moderate19 Feb 2026 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate04 Sep 2025 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
Moderate07 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High20 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High03 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Maridebart cafraglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Low13 Nov 2024 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Maridebart cafraglutide compared with its comparator?
Low21 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Petrelintide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Low19 Jan 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Petrelintide compared with its comparator?
Low11 Feb 2026
page 6 of 7